Scientists Find Way to Make Cancer Cells Easier to Kill

Scientists just found a promising new way to help your immune system fight back against cancer that spreads.

Researchers at the University of Illinois Chicago discovered a molecular switch that changes how hard or soft cancer cells are. That matters because softer cancer cells are much harder for your immune system to destroy.

"The physics of cancer are very counterintuitive," said Dr. Ekrem Emrah Er, who led the study. While tumors feel hard from the outside, the individual cancer cells inside are soft and flexible, letting them leak out and spread to other organs.

When immune cells attack soft cancer cells, they bounce off like jelly instead of shattering them like a ceramic plate. That makes it incredibly difficult for your body's natural defenses to win the battle.

The research team identified a protein called KCNMB1 that controls cell stiffness. When they activated this protein, cancer cells became stiffer and much easier for T cells and natural killer cells to attack and destroy.

The discovery gets even better. Ion channel proteins like KCNMB1 are already common drug targets, meaning doctors already use similar medications to treat heart disease and stroke.

The researchers tested an existing drug called BMS-204352 on mice with metastatic breast cancer. The treatment reduced tumor growth in the lungs and helped immune cells kill cancer cells more effectively.

"It gives us another front to fight against cancer, a biophysical front," Er said.

Why This Inspires

This discovery represents a fundamentally new approach to fighting cancer. Instead of just targeting cancer cells with chemicals or radiation, scientists can now work with the body's existing immune system by simply changing the physical properties of cancer cells.

The research builds on years of work trying to understand why metastatic cancer cells behave differently than healthy cells. First author Alexa Gajda and her team compared gene expression patterns and conducted careful experiments to pinpoint exactly which protein controlled stiffness without causing unwanted side effects.

Because drugs targeting ion channels already exist and are proven safe for other conditions, this research could move toward human trials faster than completely new medications. That shorter path from lab to patient could mean hope arrives sooner for people fighting metastatic cancer.

The team also discovered that tumors create potassium-rich environments that soften cancer cells and suppress immune responses. Activating the potassium channel reversed both problems at once.

While more research is needed before doctors can test this approach in patients, the findings offer real hope for a disease that has long evaded our best efforts.